**RESULTS**

**Figure 2:** Measured tumor size over 28 days of treatment for each group. Values are means ± SEM. ▲p < 0.05 versus G1 & G2; *p < 0.05 versus all other groups.

**Figure 3:** Tumor regression in mice treated with CT26-IT and anti-CTLA-4 in combination. Results are presented as mean ± SEM. **p < 0.05 versus G1 & G2; *p < 0.05 versus all other groups.

**Figure 4:** Tumor response to combined therapy with anti-CTLA-4 and RT. Results are presented as mean ± SEM. **p < 0.05 versus G1 & G2; *p < 0.05 versus all other groups.

**Figure 5:** Tumor growth curve for CT26 tumors treated with different combinations of therapy. Values are means ± SEM. ▲p < 0.05 versus G1 & G2; *p < 0.05 versus all other groups.

**Figure 6:** Flow cytometry analysis of TILs in CT26 tumors treated with different combinations of therapy. Values are means ± SEM. ▲p < 0.05 versus G1 & G2; *p < 0.05 versus all other groups.

**Figure 7:** Flow cytometry analysis of 4T1 metastatic lung tumors from study summarized in Figure 2.